Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis

Pharmacotherapy

Volumn 22, Issue 10, 2002, Pages 1226-1234

  Oh, Jung Mi ^a   Kyun, Ms Jinok ^a,b   Won Cho, Sung ^b  

^a Sookmyung Women's University   (South Korea)

^b Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MYALGIA; SEROCONVERSION; VIRUS LOAD; ANTIBIOTIC RESISTANCE; ASIAN; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TIME; VIROLOGY;

ADMINISTRATION, ORAL; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036794097     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.15.1226.33479     Document Type: Article

References (17)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8(suppl):S18-20.
2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study: Hepatology 1988;8:493-6.
3. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
4. Perrillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 1990;12:1433-5.
5. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
6. Dushiko GM. Treatment and prevention of chronic viral hepatitis. Pharmacol Ther 1995;65:47-73.
7. Chung HT, Lok ASF, Lai CL. Reevaluation of alfa-interferon treatment of chronic hepatitis B using polymerase chain reaction. J Hepatol 1993;17:208-14.
8. Lok ASF, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
9. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo controlled trial of recombinant α-2-interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-80.
10. Lok ASF, Lai CL, Wu PC, Leung EKY. Long-term follow-up in a randomized controlled trial of recombinant alpha-2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988;2:298-302.
11. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997;53:657-80.
12. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study Gastroenterology 1997;113:1258-63.
13. Lai CL, Liaw YF, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
14. Honkoop P, de Man RA, Niesters HG, Schalm SW. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998 29(3):510-11.
15. Aye TT, Bartholomeusz A, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-53.
16. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistance to lamivudine. Hepatology 1998;27:1670-7.
17. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.